New drug combination for newly diagnosed Philadelphia chromosome-positive ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective in treating the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with CD19-positive, BCR::ABL1-positive (Philadelphia chromosome-positive) ALL.
- You have not had prior treatment for ALL, except for a short course (up to 14 days) of certain medications like steroids or targeted therapy.
- Your kidney and liver function are within acceptable limits.
- You are willing to practice effective contraception if you or your partner can become pregnant.
- You are able to swallow oral medications without conditions that affect absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see how well the treatment works and to manage the disease, with some patients also receiving a stem cell transplant.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Hear when a new Philadelphia Positive Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.